uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
Lower non-operating expenses helped narrow the quarterly loss, while AMT-130’s 48-month primary analysis was not statistically significant.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
uniQure (NASDAQ: QURE) received FDA priority review for its Huntington’s disease therapy AMT-130, with a May 1, 2027 target decision. The application seeks accelerated approval and is supported by 36-month data from 12 high-dose patients compared with an external control. At 48 months, 12 high-dose patients showed 44% slower progression on the composite disease-rating endpoint, which was not statistically significant (p=0.144); functional capacity showed 61% slowing (nominal p=0.008). The company plans confirmatory-study screening by year-end 2026.
Third-quarter revenue rose to $5.2 million from $3.7 million a year earlier. Net loss narrowed to $61.2 million, or $0.88 per share, from $80.5 million, or $1.38 per share, despite higher research and administrative expenses. Cash and investments totaled $768.4 million at September 30, versus $622.5 million at year-end 2025; uniQure expects these resources to fund operations into 2030.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointAMT-130 received FDA priority review, with a target action date of May 1, 2027.
- Moderate pointCash and investments rose to $768.4 million at September 30, 2026, from $622.5 million at year-end 2025.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Operating funding is expected by uniQure to extend into 2030.
- Moderate pointThird-quarter net loss narrowed to $61.2 million, or $0.88 per share, versus $80.5 million, or $1.38.
- Moderate pointAMT-130’s 48-month functional-capacity result showed 61% slowing versus external control, with nominal p=0.008.
- Moderate point. Forward-looking: it has not happened yet and may not happen.FDA alignment reached on confirmatory-study design; uniQure plans screening to begin by year-end 2026.
- Moderate pointUK regulator MHRA validated AMT-130’s marketing application in the third quarter of 2026.
11 minor points
- Minor pointThird-quarter revenue increased to $5.2 million from $3.7 million a year earlier.
- Minor pointNet non-operating expense fell to $7.6 million from $20.9 million in the prior-year quarter.
- Minor pointIncome tax expense fell to $676,000 from $8.626 million in the prior-year quarter.
- Minor pointUpdated 36-month results in 15 high-dose patients showed 80% slowing on the composite endpoint, nominal p=0.005.
- Minor pointUpdated 36-month functional-capacity results showed 67% slowing in 15 high-dose patients, nominal p=0.011.
- Minor pointHigh-dose versus low-dose patients had 1.1 points less composite-score decline and 0.33 points less functional-capacity decline at 48 months.
- Minor pointCerebrospinal-fluid neurofilament light chain, a biomarker, remained near baseline at 48 months.
- Minor pointAMT-130 was generally well tolerated across 51 treated patients, with a manageable safety profile.
- Minor point. Forward-looking: it has not happened yet and may not happen.AMT-260 completed second-cohort enrollment of seven patients; uniQure expects updated results in the first half of 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.AMT-191 enrollment resumed in August 2026; uniQure expects all-cohort results in the first half of 2027.
- Minor pointLaunch preparations include building commercial-support teams and engaging U.S. Huntington’s disease treatment centers.
Negative
- Major pointAMT-130’s 48-month composite primary endpoint showed 44% slowing versus external control, not statistically significant (p=0.144).
- Minor pointThird-quarter research and development expenses rose to $35.5 million from $34.4 million a year earlier.
- Minor pointThird-quarter selling, general and administrative expenses rose to $23.9 million from $19.4 million a year earlier.
- Minor pointThird-quarter operating loss widened to $52.980 million from $51.035 million a year earlier.
- Minor pointAMT-191 dosing previously paused after liver enzyme elevations in two mid-dose patients; elevations resolved with immunosuppression.
News Explained
The planned randomization assigns patients two to one to treatment versus standard of care.
uniQure and the FDA are aligned on key elements of the confirmatory study, designed as a randomized, standard-of-care-controlled trial of about 200 patients, with Total Functional Capacity as the primary endpoint at 36 months.
Separately, the U.K. regulator validated the company’s marketing application for the therapy during the third quarter.
Details
Market move: QURE -5.33% vs previous close. Q3 2026 earnings report
On Nov 4, the day this news came out, the latest delayed price for QURE is 5.33% below the previous close. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $22.60. Relative volume is exceptionally heavy at 7.3x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- PDUFA target action date
- May 1, 2027
- Priority Review of the ifezuntirgene inilparvovec BLA
- 48-month cUHDRS slowing
- 44%; p=0.144 (non-significant)
- 12 high-dose patients versus updated external control
- 48-month TFC slowing
- 61%; nominal p=0.008
- 12 high-dose patients versus updated external control
- Confirmatory study design
- Approximately 200 patients; 2:1 randomization
- Treatment or standard of care; TFC endpoint at 36 months
- Cash, cash equivalents and investment securities
- $768.4 million
- As of September 30, 2026
- Projected operating-expense runway
- Into 2030
- Based on company resources as of September 30, 2026
- Revenue
- $5.2 million vs. $3.7 million
- Three months ended September 30, 2026 vs. the same period in 2025
- Net loss
- $61.2 million vs. $80.5 million
- Three months ended September 30, 2026 vs. the same period in 2025
Previous Earnings Reports
-
Reported $5.8M revenue, $81.1M net loss, and operating-expense runway into 2030.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pdufa regulatory
biologics license application regulatory
accelerated approval pathway regulatory
total functional capacity medical
propensity score-matched external control technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~
~ Aligned with FDA on key elements of confirmatory study design; U.S. patient screening expected to begin by end of 2026 ~
~ Cash, cash equivalents and investment securities of approximately
~ uniQure to host earnings call at 8:30 a.m. ET ~
LEXINGTON, Mass. and AMSTERDAM, Nov. 04, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2026 and highlighted recent progress across its business.
“Over the last few months, we have made significant progress in our mission to potentially deliver the first disease-modifying therapy to the patients and families living with Huntington’s disease,” said Matthew Kapusta, chief executive officer at uniQure. “We strongly believe AMT-130 has the potential to deliver meaningful benefit to HD patients. With our BLA under Priority Review and preparations for the confirmatory study underway, we are committed to bringing this therapy to patients and families who continue to live with this devastating disease.”
"As we continue to build our commercial capabilities and prepare for a potential launch, we are energized by what lies ahead, and our financial strength provides us the runway to deliver on our plans,” Mr. Kapusta continued. “We are grateful to the patients, families and investigators who have made this progress possible, and are honored to continue to work alongside this community."
Recent Company Developments and Updates
Advancing ifezuntirgene inilparvovec towards potential accelerated approval for the treatment of Huntington’s disease
- In November 2026, the U.S. Food and Drug Administration (FDA) accepted for review the Company’s Biologics License Application (BLA) for ifezuntirgene inilparvovec, submitted under the Accelerated Approval pathway. The BLA was granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027. The BLA is supported by 36-month data from 12 high-dose patients compared with a propensity score-matched external control.
- In September 2026, the Company announced additional data from its ongoing Phase I/II studies with a data cutoff of June 30, 2026.
- In the 12 high-dose patients with 48 months of follow-up, composite Unified Huntington’s Rating Scale (cUHDRS), the pre-specified primary endpoint for the analysis, showed a
44% slowing of disease progression versus the updated external control (non-significant p=0.144). Total Functional Capacity (TFC), the primary measure for the confirmatory study, showed a61% slowing (nominal p=0.008) at 48 months. At 48-months, high-dose patients compared to low-dose patients showed 1.1 points less decline on cUHDRS and 0.33 points less decline on TFC, consistent with a dose-dependent treatment effect. Cerebrospinal fluid neurofilament light chain (NfL) remained near baseline at 48 months. - An updated 36-month analysis including all 15 high-dose patients showed an
80% slowing on cUHDRS (nominal p=0.005) and a67% slowing on TFC (nominal p=0.011). - Ifezuntirgene inilparvovec was generally well tolerated with a manageable safety profile across 51 total treated patients.
- In the 12 high-dose patients with 48 months of follow-up, composite Unified Huntington’s Rating Scale (cUHDRS), the pre-specified primary endpoint for the analysis, showed a
- The Company and the FDA reached alignment on key elements of the confirmatory study of ifezuntirgene inilparvovec. The study is designed as a randomized, standard-of-care-controlled trial enrolling approximately 200 patients randomized in a 2:1 ratio to treatment or standard of care, with TFC as the primary endpoint at 36 months. The Company plans to initiate patient screening, beginning in the U.S., by the end of 2026.
- In the third quarter of 2026, the United Kingdom’s (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) validated the Marketing Authorization Application (MAA) for ifezuntirgene inilparvovec, which was submitted to the MHRA earlier in the quarter.
- The Company continues to advance its launch readiness activities, including the build out of its field medical, market access, and strategic account teams as well as engagement with U.S. Huntington’s disease treatment centers.
Continued clinical progress in pipeline programs
AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE)
- In the third quarter of 2026, the Company completed enrollment in the second dose cohort of seven patients in the ongoing Phase I/IIa study and expects to present updated results in the first half of 2027.
AMT-191 for the treatment of Fabry disease
- In August 2026, enrollment resumed in the mid- and high-dose cohorts of the ongoing Phase I/II study of AMT-191 in Fabry disease. Per protocol, dosing had previously been paused after observing asymptomatic liver enzyme elevations in two mid-dose patients, which resolved following a course of immunosuppression.
- The Company expects to present updated results from the Phase I/II study in all dosing cohorts in the first half of 2027.
Focused execution and strong financial position
- As of September 30, 2026, the Company had cash, cash equivalents and investment securities of
$768.4 million . The Company expects that these resources will be sufficient to fund projected operating expenses into 2030.
Financial Highlights
Cash Position: As of September 30, 2026, the Company held
Revenues: Revenue for the three months ended September 30, 2026 was
R&D Expenses: Research and development expenses were
SG&A Expenses: Selling, general and administrative expenses were
Non-Operating Items, net: Other non-operating items, net was an expense of
Net loss: The net loss for the three months ending September 30, 2026, was
Upcoming investor events:
- Guggenheim 3rd Annual Healthcare Conference, November 10 – Boston, MA
- Stifel 2026 Healthcare Conference, November 11 – New York, NY
- UBS Global Biopharma Conference 2026 – November 16 – London, England
Investor Conference Call and Webcast Information
uniQure management will host an investor conference call and webcast today, Wednesday, November 4th at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 5075555. If you are joining the conference call, please join 15 minutes before the start time.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com
uniQure Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," “establish,” "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," “seek,” "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Examples of these forward-looking statements include, but are not limited to, statements concerning: the Company’s cash runway and its ability to fund its operations into 2030; its belief related to the potential for ifezuntirgene inilparvovec, if approved, to meaningfully reduce disease progression based on the Company’s evaluation and view of certain measurements of disease progression the Company’s ability and plans to strategically advance its programs, including the potential commercialization of ifezuntirgene inilparvovec; the Company’s future interactions with regulatory authorities and regulatory updates related to ifezuntirgene inilparvovec ; the Company’s plans and ability to conduct a confirmatory study for ifezuntirgene inilparvovec , including the design, timing, endpoints and control arm of such study; ; and the Company’s plans to attend upcoming investor events. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: risks associated with the clinical results and the development and timing of the Company’s programs, including the risk that clinical results will be unable to demonstrate data sufficient to support further clinical development or regulatory approval in any country where approval is pursued; expectations regarding the adequacy of clinical data to support the marketing application and approval of ifezuntirgene inilparvovec; expectations regarding timing of receiving potential approval of ifezuntirgene inilparvovec; the risk that the FDA ultimately concludes that the Phase I/II trial data for ifezuntirgene inilparvovec are not sufficient to support approval of ifezuntirgene inilparvovec; the Company’s interactions with regulatory authorities, including the FDA and MHRA, which may affect the initiation, timing and progress of clinical trials and pathways and timing for regulatory approval for the Company’s other clinical candidates; the Company’s ability to conduct and fund any required confirmatory study for ifezuntirgene inilparvovec ; the Company’s ability to successfully complete any required confirmatory study for ifezuntirgene inilparvovec ; the risk that accelerated approval, if granted, may be subject to post-approval requirements that are difficult or costly to satisfy; the Company’s ability to continue to build and maintain the infrastructure and personnel needed to achieve its goals; the Company’s effectiveness in managing current and future clinical trials and regulatory processes; the continued development and acceptance of gene therapies; the Company’s ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials; the Company’s ability to obtain, maintain and protect intellectual property; and the Company’s ability to fund its operations. These risks and uncertainties are more fully described under the heading "Risk Factors" in the Company’s periodic filings with the U.S. Securities & Exchange Commission (“SEC”), including the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and, except as required by law, the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.
| uniQure Contacts: | ||
| FOR INVESTORS: | FOR MEDIA: | |
| Chiara Russo | Tom Malone | |
| Direct: 781-491-4371 | Direct: 339-970-7558 | |
| Mobile: 617-306-9137 | Mobile:339-223-8541 | |
| c.russo@uniQure.com | t.malone@uniQure.com | |
| uniQure N.V. | |||||||||
| UNAUDITED CONSOLIDATED BALANCE SHEETS | |||||||||
| September 30, | December 31, | ||||||||
| 2026 | 2025 | ||||||||
| (in thousands, U.S. dollars) | |||||||||
| Current assets | |||||||||
| Cash and cash equivalents | $ | 98,442 | $ | 80,240 | |||||
| Current investment securities | 570,021 | 542,301 | |||||||
| Accounts receivable | 4,804 | 5,863 | |||||||
| Prepaid expenses | 9,601 | 20,506 | |||||||
| Other current assets and receivables | 9,677 | 7,076 | |||||||
| Total current assets | 692,545 | 655,986 | |||||||
| Non-current assets | |||||||||
| Property, plant and equipment, net | $ | 9,923 | $ | 13,800 | |||||
| Other investments | 31,539 | 30,237 | |||||||
| Non-current investment securities | 99,967 | - | - | ||||||
| Operating lease right-of-use assets | 10,980 | 12,525 | |||||||
| Intangible assets, net | 61,855 | 72,790 | |||||||
| Goodwill | 24,503 | 25,355 | |||||||
| Deferred tax assets, net | 5,709 | 8,654 | |||||||
| Other non-current assets | 3,530 | 5,561 | |||||||
| Total non-current assets | 248,006 | 168,922 | |||||||
| Total assets | $ | 940,551 | $ | 824,908 | |||||
| Current liabilities | |||||||||
| Accounts payable | $ | 6,173 | $ | 5,170 | |||||
| Accrued expenses and other current liabilities | 50,979 | 41,292 | |||||||
| Liability related to pre-funded warrants | - | 12,595 | |||||||
| Current portion of operating lease liabilities | 2,990 | 3,862 | |||||||
| Total current liabilities | 60,142 | 62,919 | |||||||
| Non-current liabilities | |||||||||
| Long-term debt | 50,345 | 49,699 | |||||||
| Liability from royalty financing agreement | 497,271 | 473,199 | |||||||
| Operating lease liabilities, net of current portion | 9,032 | 9,832 | |||||||
| Contingent consideration | 18,742 | 18,736 | |||||||
| Deferred tax liability, net | 7,699 | 7,967 | |||||||
| Other non-current liabilities, net of current portion | 2,667 | 3,655 | |||||||
| Total non-current liabilities | 585,756 | 563,088 | |||||||
| Total liabilities | 645,898 | 626,007 | |||||||
| Shareholders' equity | |||||||||
| Total shareholders' equity | 294,653 | 198,901 | |||||||
| Total liabilities and shareholders' equity | $ | 940,551 | $ | 824,908 | |||||
| uniQure N.V. | ||||||||
| UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
| Three months ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| (in thousands, U.S dollars, except share and per share amounts) | ||||||||
| Total revenues | $ | 5,196 | $ | 3,701 | ||||
| Operating expenses: | ||||||||
| Cost of license revenues | (236 | ) | (398 | ) | ||||
| Research and development expenses | (35,517 | ) | (34,366 | ) | ||||
| Selling, general and administrative expenses | (23,918 | ) | (19,438 | ) | ||||
| Total operating expenses | (59,671 | ) | (54,202 | ) | ||||
| Other income | 1,690 | 1,510 | ||||||
| Other expense | (195 | ) | (2,044 | ) | ||||
| Loss from operations | (52,980 | ) | (51,035 | ) | ||||
| Non-operating items, net | (7,561 | ) | (20,868 | ) | ||||
| Loss before income tax expense | $ | (60,541 | ) | $ | (71,903 | ) | ||
| Income tax expense | (676 | ) | (8,626 | ) | ||||
| Net loss | $ | (61,217 | ) | $ | (80,529 | ) | ||
| Basic and diluted net loss per ordinary share | $ | (0.88 | ) | $ | (1.38 | ) | ||
| Weighted average shares used in computing basic and diluted net loss per ordinary share | 69,900,863 | 58,516,415 | ||||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When is the FDA decision expected on uniQure’s AMT-130 application?
The FDA assigned May 1, 2027 as the target action date for AMT-130’s application. The application received priority review and seeks accelerated approval for Huntington’s disease. Acceptance for review is not an approval.
What were uniQure’s third-quarter 2026 financial results?
uniQure reported revenue of $5.2 million and a net loss of $61.2 million, or $0.88 per ordinary share. The prior-year quarter had revenue of $3.7 million and a net loss of $80.5 million, or $1.38 per share. Cash and investments were $768.4 million at September 30, 2026.
How will uniQure’s AMT-130 confirmatory study be designed?
The confirmatory study is designed to enroll approximately 200 patients, randomized 2:1 to AMT-130 or standard of care. Its primary endpoint is Total Functional Capacity, a measure of patients’ ability to function, at 36 months. uniQure and the FDA reached alignment on key design elements.